Alexion nabs two EU approvals; Sun wraps buyout of GSK opiates biz; Chinese drugmakers poach Indian talent;

@FiercePharma: UPDATED: It's confirmed: 'No signal' of heart failure risk with Merck's Januvia. More | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: No change in CV risk for ACS patients on Sanofi's Lyxumia. Item | Follow @CarlyHFierce

> Alexion Pharmaceuticals ($ALXN) won final European approval for two of its drugs for ultrarare diseases, Kanuma, which treats lysosomal acid lipase deficiency, and Strensiq, a treatment for children with pediatric-onset hypophosphatasia. Report

> Sun Pharmaceutical has wrapped up its buyout of GlaxoSmithKline's ($GSK) opiates business in Australia. Report

> Chinese pharma companies have started recruiting senior scientists from Indian drugmakers to beef up their expertise in formulations, rather than bulk drug ingredients. Report

> Teva Pharmaceutical ($TEVA) said its migraine-relief patch Zecuity is now available in the U.S. Release

> Zeltia said its cancer drug Yondelis won a recommendation for approval in Japan. Report

Medical Device News

@FierceMedDev: Exact Sciences wins CMS panel vote for Cologuard pricing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Quanterix and Banyan Biomarkers forge ahead with brain injury diagnostic tech. Article | Follow @VarunSaxena2

@EmilyWFierce: Social media spin mistress @KimKardashian mops up Duchesnay's marketing mess. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Germany's coramaze receives $5M in Series A to develop transcatheter mitral valve repair device. Article

> CeQur reels in $100M for insulin infusion smart patch device. News

Biotech News

@FierceBiotech: ICYMI: Sanofi buys into Google's biotech future, pairing up in diabetes. Article | Follow @FierceBiotech

@JohnCFierce: Just wondering how Valeant's reps plan to market brodalumab. Suicidal thinking? No worries, mate. Story | Follow @JohnCFierce

@DamianFierce: "Valeant is acquiring __________ for $__________, touting the drug's __________ despite serious concerns about ___________." | Follow @DamianFierce

> Alexion wins a pair of EU approvals to build out its rare disease ranks. Story

> Gene therapy upstart Audentes bags a new program in buyout. More

> CRISPR player Intellia looks IPO-ready after $70M round. Article

Pharma Manufacturing News

> Three pharmaceutical company owners in India busted for distributing pseudoephedrine. Item

> Regis Technologies opens new facility for manufacturing highly potent APIs. Report

> Mega Lifesciences to expand in Indonesia on partnership with Sydna Farma. More

> AMRI, Saneca Pharma team to produce a range of opium-based APIs. Story

> Mayne Pharma to spend $65M on expansion of North Carolina facility. Article

Pharma Asia News

> Two dengue treatments slated for PhII in Singapore next year. Report

> Japan's MHLW gives nods for Remicade, VFend, Tracleer, INOflo new indications. Item

> Another recall by Indian drugmakers as U.S. FDA notes troubles. More

> Executive shakeup with Guilder out at Taiwan's TWi. Story

> Shanghai Pharmaceutical raises funds for online-to-offline sales push with eye on ethical products. Article

Drug Delivery News

> Surefire picks up FDA clearance for Precision cancer drug delivery tool. More

> MicroRNA specialist aims for $81M IPO amid market downturn. Report

> Teva makes only approved migraine patch available in the U.S. Story

> Intraoperative radiation therapy proving divisive among oncologists. Item

> Titan Pharma submits opioid addiction-fighting subdermal implant for FDA approval. Article

And Finally... New guidelines from the American Society of Clinical Oncology aim to help doctors make sense of newly available genetic testing. Report